CGA and systemic inflammatory response syndrome: CGA-JK3, a small molecule inhibitor of IKKβ in TLRs-associated immune responses, may be beneficial and reduce mortality of sepsis patients in whom inflammation is excessive and itself causes injury but may harm to the patients in immune suppressive stages, since sepsis leads to high morbidity and mortality through a complex pathophysiology including SIRS, compensatory anti-inflammatory response syndrome, and abnormal blood coagulation35, 36, 37, 38.